Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
Variational AI's Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in PTEN-deficient tumor models VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. ("Rakovina" or the
(Financial Post, 2025-11-24T09:02:30Z)